SCHEMBL6132569

SCHEMBL6132569

COC(=O)c1ccc(C2CCN(C(=O)O)C(C(C)(C)C)C2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
HSD17B10 Q99714 4/20 0.44
TSHR P16473 3/20 0.44
KDM4E B2RXH2 3/20 0.44
HPGD P15428 3/20 0.44
GAA P10253 2/20 0.44
CASP1 P29466 2/20 0.44
CASP7 P55210 2/20 0.44
ATM Q13315 2/20 0.44
GRIN2B Q13224 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP2C19 P33261 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HTT P42858 1/20 0.38
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM5 P08912 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9990026 0.87 MLYCD (0.38) ALDH1A1SMN1; SMN2RIPK1
SCHEMBL29136131 0.83 RIPK1 (0.49) ALDH1A1GAANPC1RAB9ASMN1; SMN2
SCHEMBL3930659 0.82 TP53 (0.41) KDM4ERIPK1
SCHEMBL2548860 0.82 BACE1 (0.37) ALDH1A1GAACYP2C19KMT2AHTT
SCHEMBL27150712 0.80 RIPK1 (0.35) ALDH1A1HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL16597962 0.78 BTK (0.45) ALDH1A1HSD17B10TSHRKDM4EHPGD
SCHEMBL22117669 0.78 RAB9A (0.41) ALDH1A1GAARAB9ACYP2C19MEN1
SCHEMBL3502629 0.77 QDPR (0.42)
SCHEMBL28532979 0.76 GPR119 (0.37) ALDH1A1SMN1; SMN2RIPK1
SCHEMBL28430267 0.75 BCHE (0.43) ALDH1A1CASP1NPC1RAB9ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 ALDH1A1 4718/4885HSD17B10 3581/4885TSHR 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.